Filing search / Iovance Biotherapeutics, Inc. / "Investigation" / Page 3

8-K

EX-1.1

le9xbdq buc18b

29 May 20

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

4:22pm

424B5

t6uubf8ft

29 May 20

Prospectus supplement for primary offering

4:15pm

424B5

z0k 0c0xf

27 May 20

Prospectus supplement for primary offering

5:26pm

S-3ASR

EX-4.1

58b afknp

27 May 20

Automatic shelf registration

4:14pm

S-3ASR

EX-5.1

cexoun8iv4

27 May 20

Automatic shelf registration

4:14pm

8-K

EX-3.1

kvtnz6h

27 May 20

Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from

4:02pm

8-K

EX-99.1

dig3v b79cbo2d

8 May 20

In the United States District Court for the District of Delaware

5:17pm

8-K

EX-99.2

457mhk7

8 May 20

In the United States District Court for the District of Delaware

5:17pm

8-K

EX-10.1

49i6id1hgmc sbtk

3 Jun 19

June 2019 © 2019, Iovance Biotherapeutics, Inc. Corporate Presentation

4:30pm